Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation outcomes

Liver Transplantation

Volumn 21, Issue 11, 2015, Pages 1347-1354

  Rodriguez, Ezequiel ^a,b   Henrique Pereira, Gustavo ^a,b   Solà, Elsa ^a,b   Elia, Chiara ^a,b   Barreto, Rogelio ^a,b   Pose, Elisa ^a,b   Colmenero, Jordi ^a   Fernandez, Javier ^a   Navasa, Miquel ^a   Arroyo, Vicente ^a,b   Ginès, Pere ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Instituto Reina Sofia de Investigacion Nefrologica IRSIN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CORTICOSTEROID; CREATININE; CYCLOSPORIN; TACROLIMUS; TERLIPRESSIN; ALBUMINOID; LYPRESSIN; VASOCONSTRICTOR AGENT;

ADULT; ARTICLE; CREATININE BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; HEPATORENAL SYNDROME; HOSPITAL ADMISSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME VARIABLE; PRIORITY JOURNAL; TREATMENT RESPONSE; TYPE 2 HEPATORENAL SYNDROME; ANALOGS AND DERIVATIVES; BLOOD; COMBINATION DRUG THERAPY; DOSE RESPONSE; DRUG EFFECTS; EPIDEMIOLOGY; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION TEST; MIDDLE AGED; MORTALITY; PROCEDURES; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; SPAIN; SURVIVAL RATE; TREATMENT OUTCOME; TRENDS; WATCHFUL WAITING;

ALBUMINS; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEPATORENAL SYNDROME; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY FUNCTION TESTS; LIVER TRANSPLANTATION; LYPRESSIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPAIN; SURVIVAL RATE; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS; WAITING LISTS; WATCHFUL WAITING;

EID: 84945913908     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.24210     Document Type: Article

References (31)

1. Moreau R, Lebrec D,. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. Hepatology 2006; 43: 385-394.
2. Ginès P, Guevara M, Arroyo V, Rodés J,. Hepatorenal syndrome. Lancet 2003; 362: 1819-1827.
3. Angeli P, Merkel C,. Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. J Hepatol 2008; 48 (suppl 1): S93-S103.
4. Ginès P, Schrier RW,. Renal failure in cirrhosis. N Engl J Med 2009; 361: 1279-1290.
5. Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al., Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23: 164-176.
6. Alessandria C, Ozdogan O, Guevara M, Restuccia T, Jiménez W, Arroyo V, et al., MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 2005; 41: 1282-1289.
7. Arroyo V, Fernandez J, Ginès P,. Pathogenesis and treatment of hepatorenal syndrome. Semin Liver Dis 2008; 28: 81-95.
8. Martín-Llahí M, Pépin MN, Guevara M, Díaz F, Torre A, Monescillo A, et al.,; for TAHRS Investigators. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008; 134: 1352-1359.
9. Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, et al.,; for Terlipressin Study Group. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134: 1360-1368.
10. Neri S, Pulvirenti D, Malaguarnera M, Cosimo BM, Bertino G, Ignaccolo L, et al., Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci 2008; 53: 830-835.
11. Krag A, Møller S, Henriksen JH, Holstein-Rathlou NH, Larsen FS, Bendtsen F,. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology 2007; 46: 1863-1871.
12. Gluud LL, Christensen K, Christensen E, Krag A,. Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev 2012; 9: CD005162.
13. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397-417.
14. Garcia-Tsao G, Lim JK,; for Members of Veterans Affairs Hepatitis C Resource Center Program. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol 2009; 104: 1802-1829.
15. Boyer TD, Sanyal AJ, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, et al.,; for Terlipressin Study Group. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transpl 2011; 17: 1328-1332.
16. Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M,. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol 2002; 14: 1363-1368.
17. Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, Martini S, et al., Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol 2007; 47: 499-505.
18. Ghosh S, Choudhary NS, Sharma AK, Singh B, Kumar P, Agarwal R, et al., Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study. Liver Int 2013; 33: 1187-1193.
19. Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, et al., The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003; 38: 258-266.
20. Cárdenas A, Ginès P,. Management of patients with cirrhosis awaiting liver transplantation. Gut 2011; 60: 412-421.
21. Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V,. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56: 1310-1318.
22. KDIGO. Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl (2011) 2012; 2: 19-36.
23. Wong F, Nadim MK, Kellum JA, Salerno F, Bellomo R, Gerbes A, et al., Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut 2011; 60: 702-709.
24. Martín-Llahí M, Guevara M, Torre A, Fagundes C, Restuccia T, Gilabert R, et al., Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastrotenterology 2011; 140: 488-496.
25. Tan HK, Marquez M, Wong F, Renner EL,. Pretransplant type 2 hepatorenal syndrome is associated with persistently impaired renal function after liver transplantation. Transplantation 2015; 99: 1441-1446.
26. Salerno F, Cazzaniga M, Merli M, Spinzi G, Saibeni S, Salmi A, et al.,; for Italian Association of the Hospital Gastroenterologists (AIGO) investigators. Diagnosis, treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice. J Hepatol 2011; 55: 1241-1248.
27. Sarin SK, Sharma P,. Terlipressin: an asset for hepatologists! Hepatology 2011; 54: 724-728.
28. Uriz J, Ginès P, Cárdenas A, Sort P, Jiménez W, Salmerõn JM, et al., Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33: 43-48.
29. Ortega R, Ginès P, Uriz J, Cárdenas A, Calahorra B, De Las Heras D, et al., Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002; 36 (pt 1): 941-948.
30. Triantos CK, Samonakis D, Thalheimer U, Cholongitas E, Senzolo M, Marelli L, et al., Terlipressin therapy for renal failure in cirrhosis. Eur J Gastroenterol Hepatol 2010; 22: 481-486.
31. Angeli P, Gines P,. Hepatorenal syndrome, MELD score and liver transplantation: an evolving issue with relevant implications for clinical practice. J Hepatol 2012; 57: 1135-1140.